[Exclusive enteral nutrition continues to be first line therapy for pediatric Crohn's disease in the era of biologics].
BACKGROUND
Exclusive enteral nutrition (EEN) has been to be more effective than corticosteroids in achieving mucosal healing without their side effects.


OBJECTIVE
To determine the efficacy of EEN in terms of inducing clinical remission in newly diagnosed CD children and to study the efficacy of this therapeutic approach in improving the degree of intestinal mucosa inflammation.


METHODS
The medical records of patients with newly diagnosed Crohn's disease treated with EEN were reviewed retrospectively. The degree of mucosal inflammation was assessed by fecal calprotectin (FC). Remission was defined as a PCDAI<10.


RESULTS
Forty patients (24 males) were included, the age at diagnosis was 11.6 ± 3.6 years. Of the 34 patients who completed the EEN period, 32 (94% per-protocol analysis) achieved clinical remission. This percentage fell to 80% in the intention-to-treat analysis. The compliance rate was 95%. Duration of EEN was 6.42 weeks (IQR 6.0-8.14). FC was significantly higher in patients with moderate and severe disease. Median baseline FC levels (680 μg/g) decreased significantly to 218 μg/g (P<0.0001) after EEN. We found a statistically significant correlation between FC and PCDAI (rho=0.727; P<0.0001). Early use of thiopurines (< 8 weeks) versus subsequent use was not associated with improved outcomes during the follow-up.


CONCLUSIONS
EEN administered for 6-8 weeks is effective for inducing clinical remission and decreasing the degree of mucosal inflammation. We did not find differences in terms of maintenance of remission in patients treated early with thiopurines.
Unidad de Gastroenterología y Nutrición Infantil. Hospital Materno Infantil, Málaga, España; Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España. Electronic address: victor.navas@gmail.com.
V M
VM
Navas-López
Unidad de Gastroenterología y Nutrición Infantil. Hospital Materno Infantil, Málaga, España; Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España.
J
J
Blasco-Alonso
Unidad de Gastroenterología y Nutrición Infantil. Hospital Materno Infantil, Málaga, España.
S
S
Lacasa Maseri
Unidad de Gastroenterología y Nutrición Infantil. Hospital Materno Infantil, Málaga, España.
F
F
Girón Fernández-Crehuet
Unidad de Gastroenterología y Nutrición Infantil. Hospital Materno Infantil, Málaga, España.
M J
MJ
Serrano Nieto
Servicio de Laboratorio, Hospital Regional Carlos Haya, Málaga, España.
M I
MI
Vicioso Recio
Unidad de Gastroenterología y Nutrición Infantil. Hospital Materno Infantil, Málaga, España; Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España.
C
C
Sierra Salinas
D001688:Biological Products / Q000627:therapeutic use*; D002648:Child; D003424:Crohn Disease / Q000628:therapy*; D004750:Enteral Nutrition; D005260:Female; D006801:Humans; D008297:Male; D012074:Remission Induction; D012189:Retrospective Studies
D001688:Biological Products
Calprotectin; Calprotectina; Crohn's disease; Enfermedad de Crohn; Enfermedad inflamatoria intestinal; Exclusive enteral nutrition; Inflammatory bowel disease; Nutrición enteral exclusiva